Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Is more testing necessary
Allison Rhodes, a primary care physician with dual board certifications in internal medicine and obesity medicine at The Ohio State University Wexner Medical Center in Columbus
"Smaller players will likely need to demonstrate either superior tolerability, novel indication-specific efficacy, meaningfully different dosing convenience, or combination strategies that address limitations of current agents, particularly muscle loss, rather than simply competing on weight-loss magnitude alone," says Nadolsky
Published December 29, 2022
Eur J Med Res 30(1):260 Rooks D, Praestgaard J, Hariry S, Laurent D, Petricoul O, Perry RG et al (2017) Treatment of sarcopenia with bimagrumab: results from a phase II, Randomized, Controlled, Proof-of-Concept study
